The CSR based on PD-1 (PD1:CD28) enhanced the effector cytokine production of human MART-1 and p53 TCR T cells upon stimulation, and increased their proliferation and tumor control in a mouse xenograft model of human melanoma [218]. This evidence concerns the gene CD28 and neoplasm.